Iovance Biotherapeutics (IOVA) Accumulated Expenses (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Accumulated Expenses of $88.1 million for Q1 2026, up 3.97% year-over-year from $84.7 million in Q1 2025, and down 20.77% quarter-over-quarter from $111.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Accumulated Expenses (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Accumulated Expenses for 16 consecutive years, with $88.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 3.97% year-over-year to $88.1 million; the TTM figure through Mar 2026 stood at $88.1 million (up 3.97% YoY), while the FY2025 annual figure was $111.2 million, up 35.66% from the prior year.
- Accumulated Expenses eased to $88.1 million in Q1 2026 per IOVA's latest filing, from $111.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $111.2 million in Q4 2025 and bottomed at $13.5 million in Q2 2022.
- Historically, Accumulated Expenses has averaged $60.5 million across 5 years, with a median of $48.9 million in 2022.
- On a YoY basis, Accumulated Expenses climbed as much as 518.97% in 2022 and fell as far as 64.44% in 2022.
- Iovance Biotherapeutics' Accumulated Expenses stood at $20.2 million in 2022, then soared by 243.8% to $69.4 million in 2023, then increased by 18.05% to $81.9 million in 2024, then surged by 35.66% to $111.2 million in 2025, then retreated by 20.77% to $88.1 million in 2026.
- Business Quant data shows IOVA's Accumulated Expenses at $88.1 million in Q1 2026, $111.2 million in Q4 2025, and $87.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.96 Mn |
| Mar 31, 2026 | 88.07 Mn |
| Dec 31, 2025 | 111.16 Mn |
| Sep 30, 2025 | 87.27 Mn |
| Jun 30, 2025 | 89.08 Mn |
| Mar 31, 2025 | 84.71 Mn |
| Dec 31, 2024 | 81.94 Mn |
| Mar 31, 2024 | 46.44 Mn |
| Dec 31, 2023 | 69.41 Mn |
| Sep 30, 2023 | 28.82 Mn |
| Jun 30, 2023 | 46.62 Mn |
| Mar 31, 2023 | 43.09 Mn |
| Dec 31, 2022 | 20.19 Mn |
| Sep 30, 2022 | 47.82 Mn |
| Jun 30, 2022 | 13.47 Mn |
| Mar 31, 2022 | 48.91 Mn |
| Dec 31, 2021 | 56.77 Mn |
| Sep 30, 2021 | 45.97 Mn |
| Jun 30, 2021 | 10.21 Mn |
| Mar 31, 2021 | 7.90 Mn |